Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab + Platinum Doublet Chemotherapy vs Chemotherapy Alone in Stage IV NSCLC (Japan)
jRCT2080223887Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, randomised trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Started Apr 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223887.